Latham & Watkins Advises on SpyGlass Pharma’s US$150 Million Initial Public Offering

SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, has announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of US$16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately US$150 million. In addition, SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP advised the underwriters in the offering with a Capital Markets team led by Orange County/Bay Area partners Shayne Kennedy and Ross McAloon, with associates Omeed Valipour, Sterling Swift, and Ariana Alemi.